A commercial method for N-acetyl-~-glucosaminidase (NAG) is described for use on a discrete analyser. Timed overnight urine was obtained from 20 healthy volunteers and 60 Type I diabetic patients for estimation of NAG (expressed in relation to creatinine) and albumin excretion rate (AER). The upper reference limit for NAG excretion in the control patients was found to be 0·25 U/mmol creatinine but was abnormally raised in 60070 of Type I diabetic patients before any increase in AER (greater than 20 JLg/min), and in 82% of patients with AER greater than 200 JLg/min. A positive correlation was found between NAG excretion and AER in Type I diabetes (r=0'61,p<0'01), but not with glycaernic control as measured by serum fructosamine levels. We conclude that measurement of NAG excretion in diabetes indicates renal tubular dysfunction or damage before any significant change in albumin excretion rate.
SUMMARY. A commercial method for N-acetyl-~-glucosaminidase (NAG) is described for use on a discrete analyser. Timed overnight urine was obtained from 20 healthy volunteers and 60 Type I diabetic patients for estimation of NAG (expressed in relation to creatinine) and albumin excretion rate (AER). The upper reference limit for NAG excretion in the control patients was found to be 0·25 U/mmol creatinine but was abnormally raised in 60070 of Type I diabetic patients before any increase in AER (greater than 20 JLg/min), and in 82% of patients with AER greater than 200 JLg/min. A positive correlation was found between NAG excretion and AER in Type I diabetes (r=0'61,p<0'01), but not with glycaernic control as measured by serum fructosamine levels. We conclude that measurement of NAG excretion in diabetes indicates renal tubular dysfunction or damage before any significant change in albumin excretion rate.
Additional key phrases: albuminuria; diabetic nephropathy; renal damage N-acetyl-~-glucosaminidase (EC 3.2.1.30; NAG) is responsible for the degradation of mucopolysaccharides and glycoproteins. Urinary NAG has its origin largely in the epithelial cells of the proximal tubule which contain a particularly large number of Iysosomes.1-2 Due to its high molecular weight, NAG cannot penetrate into the glomerular filtrate if the glomerular membrane is intact. Under normal circumstances the low level of NAG in the urine represents leakage as part of exocytotosis and pinocytotic activity of the epithelial cells. An elevated urinary NAG can occur as a result of increased metabolic activity due to increased glomerular filtration and the associated increase in reabsorption, increased excretion of exogenous substances (e.g. drugs and their associated metabolites) many of which are attacked by lysosomes or by destruction of cells in the proximal tubule (toxic damage or infections). ' An increase in the NAG excretion in the urine must invariably be interpreted as a sign of proximal cell dysfunction," the first occurrence of elevated NAG activity is usually a sign of a reversible process. It has been proposed that urinary NAG assays might have considerable potential for investigating and detecting early Correspondence: Dr K D Griffiths. 58 diabetic nephropathy. 5 Several trials investigating patients with Type I and Type II diabetes mellitus have noted that the NAG activity was raised in urine, and evidence suggested that rhis increase occurred prior to microalburninuria." A number of assays have been developed to give rapid, reliable and cost effective NAG assays, to be used as an aid to diagnosis and monitoring of diabetic nephropathy. [7] [8] Recently, the substrate 3-3I -dichlorophenylsulfonphthaleinyl-N-acetyl-~-D-glucosamide (chlorophenolred; CPR-NAG) was developed and is the basis of a kinetic method introduced by Boehringer Mannheim.
The aim of the present study was to examine the change in NAG excretion at various stages of diabetic nephropathy as measured by albumin excretion rate (AER) in timed overnight urine.
METHODS

Analytical methods
Analysis of NAG was performed using a KONE Specific discrete analyser (LABMEDICS Ltd, Stockport, UK). The assay used was Test-Combination~-NAG in Urine (Boehringer Mannheim, Germany), the lyophilized reagent was stored at 2°-6°C until required, and was stable until the expiry date shown (approximately 9 months from date of purchase). For assay calibration, Precimat {3-NAG (Boehringer Mannheim, Germany) was used, the calibration value was determined by the manufacturing company using a kinetic colorimetric test substrate of chlorophenolred-NAG (CPR-NAG).
The NAG assay procedure given with the kit was used, and modified for use on the KONE Specific analyser. Sample volume was 5 ILl, reaction buffer substrate volume 100~, incubation time 300 s, temperature 37°C, wavelength 575 nm, absorbance readings after 300 s (AI) and again after a further 300 s incubation time (A2). The absorbance change (A2-Al) was used for calculations. Evaluation of the NAG assay gave a intra-assay CV of 1'02-1'550/0, inter-assay 1· 72-2' 88%, sensitivity of 0'1 U/L and linearity extending up to 94'5 U/L. Urine albumin was measured by immunoturbidimetric assay using a diagnostic kit (Microalbuminuria, Orion Diagnostica, Finland), and the albumin excretion rate (AER) calculated. Inter-assay imprecision was 7·3% at 4·6 mg/L, 2·6% at 38·2mg/L and 4'8% at 115·2mg/L. Urine creatinine was measured by a modified Jaffe reaction using a Greiner G400 analyser (Greiner Instruments, Langenthal, Switzerland). Serum fructosamine was measured using a nitroblue-tetrazolium method (Roche Products, Welwyn Garden City, UK), automated for use on the KONE Specific discrete analyser.
PATIENTS
Timed overnight urine was obtained from 60 Type I diabetic patients (aged 23-77 years) and from 20 healthy volunteers (aged 20-51 years). The same urine collection was used for the analysis of both urinary albumin and NAG. However for NAG analysis, an aliquot of the patient urine was stored immediately after collection at -20°C. Prior to measurement the samples were thawed, and allowed to equilibrate to room temperature before analysis. We found a rapid reduction in NAG activity in urine stored at 2°_6°C over 7 days of storage. Therefore, if analysis was not performed within this period, storage at -20°C was necessary, when NAG activity was found to be stable for up to 20 weeks. To compensate for concentration differences between patient urine, all NAG results were expressed as units/mmol urine creatinine. 
STATISTICS
Statistical analysis was performed using unpaired t-test. Since NAG and albumin data were not normally distributed, non-parametric analysis was employed using Wilcoxon two sample (rank sum) test and Kendall's rank correlation coefficient. A two-tailed value was used for estimation of P.
RESULTS
The results from control (group I) and Type I diabetic patients are summarized in Table I , with the diabetic patients sub-divided into normoalbuminuric (AER < 20 /Lg/min: group 2), micro albuminuric (AER 20-200 /Lg/min: group 3) and macroalbuminuric (AER > 200 /Lg/min: group 4). Although the median AER (5,76 /Lg/min) of group 2 patients was less than 20/Lg/min, this was higher than the control group (P = O·05). There were no significant differences in age or sex between control and group 2 patients, however age was significantly greater in group 3 and 4 compared to control and group 2 diabetic patients (P<O·OI). Duration of diabetes was progressively longer with an increasing AER although this was not statistically significant (P>0·2).
The frequency distribution of the control group indicated an upper reference limit of O· 25 U/mmol creatinine (97' 5 percentile). NAG excretion data for diabetic patients were significantly higher in all groups compared to control patients (P<O·OI). NAG excretion was also significantly higher in group 4 patients compared with group 2 and 3 (P<0'05), but not significant between groups 2 and 3 (P>0·2).
The prevalence of elevated urinary NAG excretion (NAG>0·25 U/mmol creatinine) in diabetic patients is shown in Table 2 which also shows the prevalence using 0·37 U/mmol creatinine (upper reference limit + 2SD) as an additional discriminant. A significant positive AIlIl cu« Biochem 1995; 32 correlation was found between AER and NAG in Type I diabetic patients (r=0'61, P<O'OI), no correlation was found between NAG and AER in the control group, group 2 or group 3 (P> O' 05).
Mean fructosamine concentration was significantly higher in all diabetic groups compared to the control patients (P<O'OI), but no significant difference was observed between individual diabetic groups. No correlation was found in the current study between fructosamine and NAG (P>O· I) or between fructosamine and AER (P>0·2).
DISCUSSION
Our findings indicate that urinary NAG excretion was increased before any significant increase in albumin excretion rate in Type I diabetic patients, using a timed overnight urine collection for measurement of both albumin and NAG.
The use of creatinine-related data reduces the spread of data points by minimizing the variation due to differing urine collection times and diuresis-induced concentration fluctuations. Timed overnight collections reduced any variation which may have been caused by diurnal variation, allowed calculation of albumin excretion rates in /Lg/min. In this study we have presented our data for NAG in U/mmol creatinine in order to be able to make a comparison with other published data. If it would have been presented as an excretion rate (mU/min) the conclusions would have been the same.
A study on biological variation of urinary NAG in normal subjects recommended early morning urine for routine analysis, any within-subject variation was reduced by referral to creatinine." This supports the findings of Huguet et al.t? and Werle, 1 I as the proportion of pathological NAG/creatinine ratios in albuminuric patients is highest in morning urine, this measurement should provide the highest sensitivity in the detection of increased NAG activities. A timed overnight collection provided a compromise which was convenient to the patient and did not deviate too greatly from the optimum.
The significant increase in NAG in patients with a normal albumin excretion rate confirms earlier studies. 12 , 13 Using random day-time urine, NAG has been expressed per millilitre of creatinine clearance;'? although there was a significant difference between control and normoalbuminuric patients, the majority fell within the 2·5-97· 5OJo range for the control group. The large within-group variation observed in the study'? may be attributed to the time and nature of the urine samples used.
Using overnight urine collections, Gibb et a/. 13 studied NAG excretion in Type I diabetic children, and found a significant number (72%) had NAG/creatinine ratios above the normal control group reference range, compared with 60% of patients in our study. This suggests an underlying pathology before any increase in albumin excretion. This is unlikely to be due to carry-over enzymuria due to glomerular damage, since the MW of NAG (140000-150000) is well above that of albumin (69 (00). However, it could reflect tubular inflammation via an elevated lysosomal activity with elevated turnover due to an increase in albumin flux through the GBM and then increased albumin reabsorption in the proximal tubule without an increase in the AER. Although as diabetic nephropathy progresses, the albumin passing through the GBM exceeds the proximal tubules' capacity for reabsorption and the AER increases. This marks the beginning of the microalbuminuric stage (group 3). This continued effect together with other glomerular changes (mesangial expansion) leads to the development of macroalbuminuria (AER > 200 Jlg/min), and as can be seen from the data ( Table 2) , 82% of patients with this AER (group 4) have NAG activities of greater than O:25 U/mmol creatinine.
While positive correlation was found between AER and NAG excretion in diabetic patients in this study, no correlation was found in the control group. In a study by Martin et a/., 6 the urinary excretion of various proteins was documented in Type I diabetic children, and significant differences were noted in NAG excretion between the diabetic and a control group, whilst the AER was not significantly different between the patient groups, and no correlation existed between AER and NAG activities. The patients groups used were analogous Urinary NAG activity 61 to patients in group 1 and 2 in this study, with the diabetic patients representing a period in the disease process before any change in AER takes place. The findings are also similar, with NAG activities significantly increased before any change in AER. In the UK Prospective Diabetes Study (1993)14 correlations between AER and NAG were made with hypertension and glycaemia in Type II diabetes when it was concluded that AER was associated with hyperglycaemia but hypertension and NAG with hyperglycaemia. Also of considerable interest, is the association of NAG excretion in diabetics with the degree of glycaemic control, assessed in the current study by measurement of serum fructosamine levels. The mean fructosamine concentrations for the various patient groups showed no significant difference and no correlation existed between serum fructosamine and NAG excretion or between fructosamine and AER. Other studies'v'" have found significant correlations between NAG excretion and glycosylated haemoglobin (HbA 1c ) , indicating that care must be exercised when interpreting fructosamine data and making a parallelism to HbA lc in studies such as this.
Measurement of urinary NAG by this method seems to provide an early non-invasive biochemical test for renal damage, which was reliable and rapid. The increased NAG activity observed in diabetic patients in this study and in others" suggests that tubular function is affected in the early stages of diabetes prior to any increase in albumin excretion rate and may be one of the earliest abnormalities of renal function in Type I diabetes. Earlier reports indicating the apparent lack of tubular damage in early diabetic nephropathy.!? as determined by normal fJ-2 microglobulin excretion in 24 h urine collections'S'? may be misleading because of the instability of fJ-2 microglobulin easurernent in urine at physiological pH.
Glomerular changes occur early in diabetes and initially the tubular cells can reabsorb the increased albumin load, resulting in normal albumin excretion rate but increased lysosomal activity and NAG excretion. The next stage is characterized by an increase in both NAG and albumin, and this indicates that proximal cell reabsorption capacity has been exceeded. Further increase in NAG excretion will accompany a loss in the functional capacity of the cell leading to structural breakdown which ultimately results in cell necrosis. Only long-term studies will show whether increased NAG excretion in diabetes is a more sensitive predictor of the subsequent increases in AER and accompanying diabetic nephropathy.
